The Cancer Research Group focusses on identification and validation of biomarkers predictive of responsiveness to treatment as well as identification of prognostic markers.
A particular specialism of the laboratory is glycoproteomics. We have developed methods for medium-throughput screening of biomarkers from body fluids and tissues.
The availability of plasma, serum and urine samples and DNA collected through the DietCompLyf study allows the comparison between samples from patients with different clinical outcome. Tissue samples from breast cancer patients allow validation of the markers detected in serum and other bodily fluids.
Studies are taken in collaboration with our partners.